{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-126639","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.306694+00:00","generated_at":"2026-06-07T11:29:01.846397+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GSBR-1290 Phase 2a meets endpoints; significant HbA1c and weight reductions in T2DM and obesity","bullets":["HbA1c reduction: -1.01% to -1.02% placebo-adjusted at Week 12 (p≤0.008).","Weight loss: T2DM -3.26% to -3.51% placebo-adjusted at Week 12; obesity -4.74% at Week 8 (p<0.0001).","No treatment-related SAEs; 2.8% discontinuation rate due to AEs; GI events most common.","Full 12-week obesity data expected Q2 2024; Phase 2b obesity study to start H2 2024.","Toxicology studies show >100-fold safety margin; Japanese bridging study supports global plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-126639","json":"https://secwatch.observer/filing/0001104659-23-126639.json","markdown":"https://secwatch.observer/filing/0001104659-23-126639.md","text":"https://secwatch.observer/filing/0001104659-23-126639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923126639/0001104659-23-126639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923126639/tm2329572d16_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:29:01.846397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}